Navigation Links
University at Albany: Governor Cuomo Announces Israeli Biotech Company Creating New Economic Opportunity In Capital Region

ALBANY, N.Y., Jan. 13, 2014 /PRNewswire-USNewswire/ -- Governor Andrew M. Cuomo today announced that BioHarvest Ltd., an Israeli biotechnology company, is creating new economic opportunity in the Capital Region by moving its research and development start-up operations from Tel Aviv, Israel to Albany and creating 60 new jobs. The company will collaborate with the University at Albany's Cancer Research Center (CRC) to produce innovative technologies for human health, including functional health food products and intervention strategies based on the cultured cells of fruits and vegetables, in three phases.


"Companies in growing fields from around the globe are coming to New York and creating new economic opportunity in all parts of our state," Governor Cuomo said. "This partnership with BioHarvest will create new jobs and continue to establish the Capitol Region as a leader in the research and development field. We will continue to collaborate with up and coming companies to generate jobs and transform New York's economy."

Founded in 2007 as Fruitura BioScience Ltd, the woman co-owned and managed Israeli biotechnology company has developed a patented, state-of-the-art platform to grow and bio-harvest fruit cell cultures in 3D bioreactors. The unique technology enables the production of safe and clinically researched super-foods rich in phytonutrients in highly bio-available and efficacious forms, which are produced on an industrial scale for the nutrition, wellness, and supplements markets. Along with New York State's highly competitive economic development agenda— including Governor Cuomo's Regional Economic Development Councils and START-UP NY program—and the Capital Region's unique asset as a fast growing hub for high-tech industries, BioHarvest was attracted by the University at Albany's extraordinary research strengths and the prospect of developing a strong, public-private partnership with Cancer Research Center scientists at the University's East Campus.

University at Albany President Robert J. Jones said, "With the innovative science and technologies of the Cancer Research Center complemented by the resources of the State of New York through Empire State Development, the collaboration with BioHarvest is a model public-private partnership clearly illustrating how the discovery, innovation and entrepreneurship equation creates jobs and positive economic outcomes for the community."

In early 2013, BioHarvest's first large-scale commercial product, red grape cell powder (RGC), now referred to as "Vinia," was given the designation of a novel food by the Israeli regulatory agencies, one of only six functional foods so classified in Israel. Pre-clinical and clinical studies demonstrated that Vinia had beneficial effects on cardiovascular disease, Type II diabetes, and metabolic conditions. In addition, in the United States, Vinia has been determined to be GRAS, or Generally Recognized as Safe.

BioHarvest's technology is a new paradigm for deriving health benefits from super-foods. It delivers super-foods with phytonutrients present in all-natural, unblocked and unaltered form, resulting in high bioavailability without extraction by solvents, genetic modification, or synthetic molecular processing.

"Most of us are aware of the health benefits of the French Paradox phenomenon: reduced incidence of coronary heart disease, anti-inflammatory activity, mitigation of metabolic disorders and anti-aging properties," explained Yochi Hagay, Ph.D., CEO and Co-Founder, BioHarvest Ltd. "Vinia provides all of those French Paradox benefits for proactive health management."

The BioHarvest and Cancer Research Center partnership will unfold in three phases:

  1. Scientific and clinical collaborations for research into health and intervention strategies. Studies are already in progress and four to five staff members are expected to be hired as part of this phase.
  2. The building of a site on the East Campus to house four, five-ton bioreactors and production and sales facilities. This phase will generate as many as 50 jobs and is expected to begin by the end of 2014 or 2015.
  3. The establishment of a Center for Innovative Functional Foods Research to study the underlying biology of bioactive compounds in red grape cell powder and other functional foods and create a data set for all functional foods. This phase will produce up to 10 local jobs.

A $1.2 million Empire State Development (ESD) award through the Capital Region Economic Development Council (CREDC) will assist BioHarvest in start-up expenditures, supporting the partnership with the University at Albany and the creation of 60 new jobs. The ongoing development of the regional Biotechnology Corridor and the availability of highly qualified trained personnel from the Cancer Research Center's bioinstrumentation degree program, also funded by an ESD award, solidified the commitment by BioHarvest.

"BioHarvest's decision to expand its key start-up operations to the University at Albany's East Campus highlights the Capital Region's strength in growing high-tech, emerging industries and the unparalleled asset that institutions like UAlbany are for New York State," said Empire State Development President, CEO & Commissioner Kenneth Adams. "We welcome BioHarvest to New York State and are proud to support the development of a ground-breaking product and the creation of dozens of jobs in the expanding fields of science, technology, engineering and math."

"I am thrilled that BioHarvest has decided to invest right here in the Capital Region," said James J. Barba, Co-chair of the Capital Regional Economic Development Council and President and CEO of the Albany Medical Center.  "This novel public-private partnership between BioHarvest and the University at Albany will not only lead to the development of innovative technologies and healthy functional foods, but profoundly underscores how Tech Valley is advancing.  Today's announcement is also a reminder of how the Governor's REDC program is supporting economic growth in numerous ways including bringing science, innovation and technology together to make the lives of those around us better."  

"Vinia and other preparations produced using this bioreactor technology contain all the bioactive compounds produced in red grape cells, and it is this combination of botanicals that are responsible for the beneficial effects of Vinia," said Martin Tenniswood, Director, UAlbany Cancer Research Center. "The Cancer Research Center looks forward to our collaboration with BioHarvest to investigate the chemo-preventive properties of Vinia and other botanical preparations."  

About the Cancer Research Center
The central mission of the University at Albany Cancer Research Center is to conduct research and provide training related to understanding the genetic and environmental causes of cancer. The basic research mission is focused on the underlying biology associated with tumor initiation and progression, and the development and evaluation of chemopreventive regimens and therapeutic approaches for common cancers. To this end, the Cancer Research Center houses fully staffed, comprehensive, state of the art research facilities.

Faculty at the Cancer Research Center are dedicated to providing a collaborative research environment within the University at Albany School of Public Health and its affiliated Wadsworth Research Laboratories of the New York State Department of Health to foster the training of graduate students and postdoctoral fellows in cancer biology.

Educationally and culturally, the University at Albany-SUNY puts "The World Within Reach" for its more than 17,300 students. An internationally recognized research university with 118 undergraduate majors and minors and 138 graduate programs, UAlbany is a leader among all New York State colleges and universities in such diverse fields as criminal justice, information science, public administration, social welfare, business and sociology. With a curriculum enhanced by 500 study-abroad opportunities, UAlbany launches great careers. Visit UAlbany's extensive roster of faculty experts.






Contact: Media Relations (518) 956-8150

SOURCE University at Albany
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Arizona State University engineers aim to improve performance of technology in extreme environments
2. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
3. Causes of Gulf War Illness are complex and vary by deployment area -- Baylor University study
4. HistoRx Licenses Melanoma Assay from Yale University
5. Epitomics, Inc. and University of California, Davis, Complete Star Program for High-Throughput Measurement of Antibody-Antigen Interactions
6. Boulder Diagnostics Licenses Novel Rapid Detection Technology for Homocysteine and Related Compounds from Portland State University
7. Research at Rice University leads to nanotube-based device for communication, security, sensing
8. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
9. Valkee and University of Oulu Publish the First Clinical Trial on Bright Light Therapy Channeled via ear Canals in Seasonal Depression
10. Oxitec Responds to University of Panamas Forum on Transgenic Mosquitoes
11. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
Post Your Comments:
(Date:2/2/2019)... ... February 01, 2019 , ... Biomatlante, a world leader in ... CEO, Julien Dert, being effective on February 1st, 2019. , Graduated from ICN ... in which more than 12 years in the Medical Device industry. Chief Financial ...
(Date:1/30/2019)... ... January 29, 2019 , ... Actus Therapeutics, a ... of the first patient in a phase 1/2 clinical study of ACTUS-101 in ... high morbidity and often leads to premature death. There are variable rates ...
(Date:1/30/2019)... ... 2019 , ... Through its Microbiome Grant Initiative , ... design, planning, sample collection, and analysis to a team of researchers at North ... the interactions between gut microbial composition and cardiovascular health risks, such as hypertension ...
(Date:1/24/2019)... ... January 22, 2019 , ... Dr. Douglas Stramel of Advanced Care Veterinary ... Therapy System (V-PET™) for nearly three years. A proponent of Regenerative Medicine, ... 2007 and began using V-PET™ 2016. V-PET™ is a gravity filtration-based platelet therapy ...
Breaking Biology Technology:
(Date:1/24/2019)... ... January 23, 2019 , ... rHEALTH LLC, an innovative digital ... from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application ... (DMI). This application covers the addition of a length scale to hydrogel microparticles. ...
(Date:1/20/2019)... ... January 17, 2019 , ... ... drug metabolism and distribution has been documented for many years. These observed differences ... terms of adverse event profiles in patients residing in different geographic regions. This ...
(Date:1/10/2019)... (PRWEB) , ... January 10, 2019 , ... When Dr. ... Asymmetrex , was invited to contribute a chapter to the new book Perinatal ... wanted to continue Asymmetrex’s effort to address a debilitating secret of stem cell medicine. ...
Breaking Biology News(10 mins):